---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-009508"
form_type: "8-K"
ticker: "GANX"
cik: "0001819411"
company_name: "Gain Therapeutics, Inc."
filed_at: "2023-05-12T23:59:59+00:00"
generated_at: "2026-06-15T02:43:42.880436+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Gain Therapeutics Q1 net loss widens to $5.1M; cash $18.8M supports ops into Q3 2024

## Summary
- Net loss of $5.1M ($0.43/shr) vs $3.3M ($0.28/shr) YoY; R&D spend rose to $2.8M on pre-IND studies.
- Cash and marketable securities $18.8M at March 31, 2023; ATM proceeds in April extend runway into Q3 2024.
- Completed GLP toxicology for GT-02287 (GBA1 Parkinson's); Phase 1 application to Australian HREC expected mid-2023.
- Secured $2.8M Innosuisse grant for GT-02287 and $1.3M EU consortium grant for AAT program.
- Appointed C. Evan Ballantyne as CFO in April 2023.

## SEC filing metadata
- accession: 0001558370-23-009508
- form_type: 8-K
- ticker: GANX
- cik: 0001819411
- company_name: Gain Therapeutics, Inc.
- filed_at: 2023-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819411/000155837023009508/0001558370-23-009508-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819411/000155837023009508/ganx-20230512x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-009508
- JSON: https://secwatch.observer/filing/0001558370-23-009508.json
- Plain text: https://secwatch.observer/filing/0001558370-23-009508.txt

## Key facts
- Earnings Releases
  Gain Therapeutics, Inc. reported first quarter ended March 31, 2023 results: revenue $55,180, net income $5.1 million, EPS $0.43 per share basic and diluted.
  - Period: first quarter ended March 31, 2023
  - Revenue: $55,180
  - Net income: $5.1 million
  - EPS: $0.43 per share basic and diluted
  - Result: reported results
  source text: CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ ​ 2023 2022 Revenues: ​ ​ ​ Collaboration revenues ​ $ 55,180 ​ $ 37,538 ​ Other income ​ - ​ 7,468 ​ Total revenues ​ ​ 55,180 ​ ​ 45,006 ​ ​ ​ ​ ​ ​ ​ ​ ​ Operating expenses: ​ ​ ​ ​ ​ Research and development ​ ​ (2,791,205
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819411/000155837023009508/0001558370-23-009508-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.